Stockreport

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination [Yahoo! Finance]

Sagimet Biosciences Inc. - Series A  (SGMT) 
PDF Primary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combination Topline data are anticipated in the first ha [Read more]